Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor mobilization patients with hematological malignancies. All eligible patients will receive EAP regimen treatment, then the number of CD34+ cells and white blood cells will be monitoring. When the collection standard is met, hematopoietic stem cell collection will be started.
Inclusion Criteria:
Exclusion Criteria:
Patients with severe cardiac, hepatic or renal insufficiency, such as:
Patients with active infection.
History of allergy to Etoposide (VP-16), Cytarabine (Ara-C), or PEG-rhG-CSF.
Women who are pregnant or breastfeeding.
Have received live vaccine and attenuated live vaccine within 4 weeks before enrollment.
For any other reasons, the patients are believed not suitable for participation in this study by investigators
814871416@qq.com86-13486090834
39612903@qq.com86-13685832706
Dongyang, Zhejiang, China
wugongqiang59@126.com13757950788
Hangzhou, Zhejiang 310024, China
Shaoxing, Zhejiang 312000, China
jianghuifang501@163.com+86-13957182087
drwjyu@163.com+8613750853563
SLH077@126.com13587206019
huhuixian@zju.edu.cn+86-13588652288
huanglixiaoyu@126.com+86-13566782316
Lilinjie0394@163.com+86-13567615761
39612903@qq.com86-0574-87016871
fengweiying1997@126.com+86-13588570250
yin990216@sina.com+86-18767509030
chens7111@tzzxyy.com13575809591
hyperlool@126.com+86-13758628257